Microglia homeostatic function is compromised in the states of chronic inflammation associated with neurodegenerative disease, which contribute to neuronal dysfunction, neurodegeneration, and ultimately dementia. However, microglia are very difficult cells to study in culture or in rodent in vivo models of age-related neurodegenerative diseases because they do not fully replicate the human condition. Thus, new and innovative models systems are needed to authentically interrogate microglial biology.
Tiaki’s platform technology enables discovery and validation of targets that restore normal, homeostatic functions of microglia in the central nervous system. Tiaki’s small molecule targets will restore normal microglia function and resolve disease pathophysiology, an approach that is complimentary to others, including those that target Aβ reduction and clearance.
We are passionate about this because there is a pressing need for validation, discovery and development oftherapeutics based on innovative targets and mechanisms for diseasemodification for all forms of dementia.
Meet the Team:
Barbara Tate, CEO
Kelley C. Larson, Principal Scientist
Lauren Martens, Director, Biology